Why we exist
We exist to help end malaria. Although there is now a good research pipeline of antimalarials in response to the rapid spread of drug resistant malaria, there is very little evidence on how these drugs should best be deployed.
Our research focuses around four major themes:
- Access: The poorest are the most likely to have limited or no access to antimalarials.
- Targeting: In some settings the great majority of those given an antimalarial do not actually have malaria.
- Safety: Methods of detecting side-effects of new drugs when used at scale are rudimentary and little data exists on potentially important interactions e.g. with antiretrovirals.
- Quality: There is no system for identifying fake and substandard antimalarials despite clear evidence of a major market in fake new antimalarials.
Policy-makers are currently having to make major decisions on how best to deploy ACTs with little or no relevant evidence. We hope to answer key questions on ACT delivery so that policy-makers will have the evidence they need.